GCT represents a large and growing market for novel therapeutics that includes various clinical areas, manufacturing, regenerative medicine and tools and platforms. Bayer’s recently announced cell and gene therapy platform positions the company to be a major player in virtually all of these segments. How does a Company like Bayer manage the development of a portfolio in such a large and diverse space? How does Bayer approach the support of the production infrastructure with its unique demands and significant differences from its historical requirements?